聚肌胞与刺五加伍用对乙肝感染者的疗效观察

Study on the Efficacy of IFN—inducer Poly Ⅰ: C Combined with "CIWUJIA" Against Chronic HBsAg Positive Individuals

用小剂量干扰素诱导剂>PolyI:C及免疫刺激剂刺五加配伍,治疗慢性乙肝感染者32例(慢迁肝12例,无症状HBsAg携带者20例),同时以26例(慢迁肝11例,无症状HBsAg携带者15例)作为治疗对照。三个月后,治疗组病例血清HBsAg滴度显著下降,而对照组则反见滴度上升,两组比较HBsAg滴度下降率分别为59.38％及7.69％(P<0.0001)。治疗组无滴度上升者,对照组有30.77％的病例滴度上升(P<0.001)。此外,治疗组肝功能絮状试验有明显好转,与对照组有显著差异(p<0.05)。血清中的HBsAg滴度降低,可能间接反映出降低了的病人及携带者的传染性,值得进一步研究提高其疗效。

A clinical study on the therapeutic efficacy of IFN-inducer Poly Ⅰ:C combined with 'Ciwujia' (mainly containing Acanthopenax senticosus) against 32 HBsAg positive individuals (including 12 chronic persistent hepatitis and 20 chronic asymptomatic carriers) had been carried out in a three-month period. At the same time, 26 individuals (random, including 11 GPH and 15 carriers) treated with common vitamins served as controls. 3 months after the treatment, HBsAg titers (GMT) in individuals of poly Ⅰ:C-Ciwujja group (group P) were apparently decreased,The percentage of tiler decrease of the group was 59.38％, but it was only 7.67％ in the control group (group C). Statistically, the difference between the two groups was highly significant (P<0.0001). No one had been found as HBsAg titer increasing in group P, but there were 30.77％ cases of group C increased (P<0.001, see Tab. 1&2). On the other hand, the turbidity tests of liver function showed difference betwteen the two groups. Results of TTT of most cases in group P were more remarkablly improved (see Tab. 3) than that of group C(P<0.05). It is considered that the decrease of HBsAg titers in sera might mean decreased infectivity of patients with hepatitis B and asymptomatic HBsAg carriers. So that it is necessary to have more research for further benifits.